Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ADAP Adaptimmune Therapeutics PLC
- Stocks
- Healthcare
- NASDAQ: ADAP
Price (delayed)
$0.272
Market cap
$72.24M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.24
Enterprise value
$77.94M
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform
Highlights
Adaptimmune Therapeutics's EPS has soared by 64% YoY and by 20% from the previous quarter
Adaptimmune Therapeutics's net income has surged by 57% YoY
The debt has surged by 106% year-on-year but it has declined by 34% since the previous quarter
The company's quick ratio fell by 46% QoQ and by 45% YoY
Key stats
What are the main financial stats of ADAP
Market
Valuations
Earnings
Shares outstanding
265.58M
Market cap
$72.24M
Enterprise value
$77.94M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.43
Revenue
$179.64M
Gross profit
$178.69M
Operating income
-$65.23M
Net income
-$69.9M
EBIT
-$61.04M
EBITDA
-$50.18M
Free cash flow
-$109.84M
Per share
Balance sheet
Liquidity
EPS
-$0.24
EPS diluted
-$0.3
Free cash flow per share
-$0.43
Book value per share
-$0.15
Revenue per share
$0.7
TBVPS
$0.6
Total assets
$158.07M
Total liabilities
$195.5M
Debt
$48.71M
Equity
-$37.43M
Working capital
$51.93M
Debt to equity
-1.3
Current ratio
2.02
Quick ratio
1.29
Net debt/EBITDA
-0.11
Margins
Efficiency
Dividend
EBITDA margin
-27.9%
Gross margin
99.5%
Net margin
-38.9%
Operating margin
-36.3%
Return on assets
-26.8%
Return on equity
-185.5%
Return on invested capital
-44.9%
Return on capital employed
-57%
Return on sales
-34%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADAP stock price
How has the Adaptimmune Therapeutics stock price performed over time
Intraday
8.8%
1 week
-9.33%
1 month
16.29%
1 year
-76.35%
YTD
-49.51%
QTD
38.07%
Financial performance
How have Adaptimmune Therapeutics's revenue and profit performed over time
Revenue
$179.64M
Gross profit
$178.69M
Operating income
-$65.23M
Net income
-$69.9M
Gross margin
99.5%
Net margin
-38.9%
ADAP's operating margin has soared by 97% YoY and by 6% QoQ
The net margin has surged by 96% year-on-year and by 2.3% since the previous quarter
ADAP's operating income has soared by 66% YoY and by 5% from the previous quarter
Adaptimmune Therapeutics's net income has surged by 57% YoY
Price vs fundamentals
How does ADAP's price correlate with its fundamentals
Growth
What is Adaptimmune Therapeutics's growth rate over time
Valuation
What is Adaptimmune Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
0.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.43
Adaptimmune Therapeutics's EPS has soared by 64% YoY and by 20% from the previous quarter
The P/S is 100% below the 5-year quarterly average of 93.6 and 65% below the last 4 quarters average of 1.1
Efficiency
How efficient is Adaptimmune Therapeutics business performance
Adaptimmune Therapeutics's ROS has soared by 96% YoY and by 5% from the previous quarter
The company's return on invested capital has surged by 64% YoY and by 11% QoQ
Adaptimmune Therapeutics's return on assets has surged by 52% YoY but it has decreased by 8% QoQ
The return on equity has declined by 39% since the previous quarter but it is up by 21% year-on-year
Dividends
What is ADAP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADAP.
Financial health
How did Adaptimmune Therapeutics financials performed over time
ADAP's total assets is 19% smaller than its total liabilities
The company's quick ratio fell by 46% QoQ and by 45% YoY
ADAP's total assets is down by 39% year-on-year and by 36% since the previous quarter
ADAP's debt to equity has dropped by 121% since the previous quarter
The debt has surged by 106% year-on-year but it has declined by 34% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.